Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Irina Proskorovsky, Agnes Benedict, Sylvie Negrier, Danielle Bargo, Rickard Sandin, Krishnan Ramaswamy, Jigar Desai, Joseph C. Cappelleri, James Larkin

ABSTRACT

BACKGROUND: In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. METHODS: Progression-free survival (PFS) and overall survival (OS) in prior sunitinib-treated patients with mRCC were compared by conducting matching-adjusted indirect comparison (MAIC) analyses, including base-case and sensitivity analyses. Individual patient-level data from prior sunitinib-treated patients who received axitinib in AXIS were weighted to match published baseline characteristics of prior sunitinib-treated patients who received either cabozantinib or everolimus in METEOR. RESULTS: There was no statistically significant difference in PFS (aHR [adjusted hazard ratio] = 1.15 [CI: 0.82-1.63]) and OS (aHR = 1.00 [CI: 0.69-1.46]) between axitinib versus cabozantinib in the base-case analysis. In the sensitivity analysis, PFS (aHR = 1.39 [CI: 1.00-1.92]) and OS (aHR = 1.35 [CI: 0.95-1.92]) were shorter for axitinib compared with cabozantinib; however, the OS difference was not statistically significant. Axitinib was associated with significantly longer PFS compared with everolimus in the base-case (aHR = 0.53 [CI: 0.36-0.80]) and sensitivity analyses (aHR = 0.63 [CI: 0.45-0.88]), respectively. Results suggested an OS benefit for axitinib versus everolimus in base-case analyses (aHR = 0.63 [CI: 0.42-0.96]); however, the difference in OS in the sensitivity analysis was not statistically significant (aHR = 0.84 [CI: 0.59-1.18]). CONCLUSIONS: MAIC analyses suggest PFS and OS for axitinib and cabozantinib are dependent on the Memorial Sloan Kettering Cancer Center definition used; in the base-case analysis, there was no significant difference in PFS and OS between axitinib and cabozantinib. In the sensitivity analysis, PFS in favour of cabozantinib was significant; however, the trend for prolonged OS with cabozantinib was not significant. For axitinib and everolimus, MAIC analyses indicate patients treated with axitinib may have an improved PFS and OS benefit when compared to everolimus. Disparities between the base-case and sensitivity analyses in this study underscore the importance of adjusting for the differences in baseline characteristics and that naïve indirect comparisons are not appropriate. More... »

PAGES

1271

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0

DOI

http://dx.doi.org/10.1186/s12885-018-5157-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110759467

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30567533


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Axitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Evidera, 7575 Trans-Canada Highway, Suite 404, H4R 1V6, Montreal, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Proskorovsky", 
        "givenName": "Irina", 
        "id": "sg:person.0723163720.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723163720.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Evidera, Budapest, Hungary"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benedict", 
        "givenName": "Agnes", 
        "id": "sg:person.01067707272.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067707272.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Lyon, Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Negrier", 
        "givenName": "Sylvie", 
        "id": "sg:person.0723756046.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bargo", 
        "givenName": "Danielle", 
        "id": "sg:person.010375770560.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010375770560.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (Sweden)", 
          "id": "https://www.grid.ac/institutes/grid.420142.1", 
          "name": [
            "Pfizer AB, Vetenskapsv\u00e4gen 10, 191 90, Sollentuna, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sandin", 
        "givenName": "Rickard", 
        "id": "sg:person.0756726716.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756726716.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramaswamy", 
        "givenName": "Krishnan", 
        "id": "sg:person.0600603143.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600603143.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desai", 
        "givenName": "Jigar", 
        "id": "sg:person.01132720503.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132720503.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cappelleri", 
        "givenName": "Joseph C.", 
        "id": "sg:person.01340453362.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340453362.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Royal Marsden NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larkin", 
        "givenName": "James", 
        "id": "sg:person.01255356274.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-0553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003173433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.4809", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003290766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2162-3619-2-32", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008593355", 
          "https://doi.org/10.1186/2162-3619-2-32"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-12-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010370832", 
          "https://doi.org/10.1186/1471-2288-12-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70093-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017252421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2012.05.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017355577"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/03007995.2016.1140028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020375126"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696998.2013.768530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020783661"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.06.132", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022235480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11592490-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024355436", 
          "https://doi.org/10.2165/11592490-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/03007995.2014.977992", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025383996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/cer.s97885", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037697585"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70484-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043226190"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2007.03.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047653672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40263-013-0102-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048158014", 
          "https://doi.org/10.1007/s40263-013-0102-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40263-013-0102-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048158014", 
          "https://doi.org/10.1007/s40263-013-0102-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2015.09.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051027115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0184423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091532595"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41416-018-0164-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106858927", 
          "https://doi.org/10.1038/s41416-018-0164-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials.\nMETHODS: Progression-free survival (PFS) and overall survival (OS) in prior sunitinib-treated patients with mRCC were compared by conducting matching-adjusted indirect comparison (MAIC) analyses, including base-case and sensitivity analyses. Individual patient-level data from prior sunitinib-treated patients who received axitinib in AXIS were weighted to match published baseline characteristics of prior sunitinib-treated patients who received either cabozantinib or everolimus in METEOR.\nRESULTS: There was no statistically significant difference in PFS (aHR\u2009[adjusted hazard ratio]\u2009=\u20091.15 [CI: 0.82-1.63]) and OS (aHR\u2009=\u20091.00 [CI: 0.69-1.46]) between axitinib versus cabozantinib in the base-case analysis. In the sensitivity analysis, PFS (aHR\u2009=\u20091.39 [CI: 1.00-1.92]) and OS (aHR\u2009=\u20091.35 [CI: 0.95-1.92]) were shorter for axitinib compared with cabozantinib; however, the OS difference was not statistically significant. Axitinib was associated with significantly longer PFS compared with everolimus in the base-case (aHR\u2009=\u20090.53 [CI: 0.36-0.80]) and sensitivity analyses (aHR\u2009=\u20090.63 [CI: 0.45-0.88]), respectively. Results suggested an OS benefit for axitinib versus everolimus in base-case analyses (aHR\u2009=\u20090.63 [CI: 0.42-0.96]); however, the difference in OS in the sensitivity analysis was not statistically significant (aHR\u2009=\u20090.84 [CI: 0.59-1.18]).\nCONCLUSIONS: MAIC analyses suggest PFS and OS for axitinib and cabozantinib are dependent on the Memorial Sloan Kettering Cancer Center definition used; in the base-case analysis, there was no significant difference in PFS and OS between axitinib and cabozantinib. In the sensitivity analysis, PFS in favour of cabozantinib was significant; however, the trend for prolonged OS with cabozantinib was not significant. For axitinib and everolimus, MAIC analyses indicate patients treated with axitinib may have an improved PFS and OS benefit when compared to everolimus. Disparities between the base-case and sensitivity analyses in this study underscore the importance of adjusting for the differences in baseline characteristics and that na\u00efve indirect comparisons are not appropriate.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-018-5157-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses", 
    "pagination": "1271", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3ef2fb80629bf314a50551c6f0d3bd4837131769f19d8a673511f34415ded062"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30567533"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-5157-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110759467"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-5157-0", 
      "https://app.dimensions.ai/details/publication/pub.1110759467"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78964_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-018-5157-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      21 PREDICATES      67 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-5157-0 schema:about N01855a0b8dec430dbafbe4defc5f4980
2 N1d27006780c44477a4f54b635a6033bc
3 N384b6824adfa4659a86646f2536774da
4 N3d2ad73210b44306b88b7060378d9c7f
5 N680f30ed24c9440689cbb2088fba7643
6 N6b8675a6e589412fb5a25f3ccfdc4b40
7 N6e1dab7abe3e4dbf9de786a47651a956
8 N8740b4a7821542af9b6dad66cd2b2d5e
9 N89ff103c60f940d7b2e24c19dcab254d
10 N9b3d1b4a71b94f3489aa2192a6b61a51
11 Na5be7009bcc14e19907dd1b80e23ab0c
12 Nb8a5c55fca8749b09db47c412d86db7c
13 Nc2801585b20841ea9956723627213a26
14 Nec07896628dc49e9b8444d150a7c5aae
15 Nff494e8630c149e7b42c1cead3b1a854
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nf006f7859a264303a51665afd19c9cd0
19 schema:citation sg:pub.10.1007/s40263-013-0102-x
20 sg:pub.10.1038/s41416-018-0164-0
21 sg:pub.10.1186/1471-2288-12-9
22 sg:pub.10.1186/2162-3619-2-32
23 sg:pub.10.2165/11592490-000000000-00000
24 https://doi.org/10.1002/cncr.25219
25 https://doi.org/10.1016/j.clinthera.2015.09.013
26 https://doi.org/10.1016/j.eururo.2007.03.035
27 https://doi.org/10.1016/j.jval.2012.05.004
28 https://doi.org/10.1016/s0140-6736(08)61039-9
29 https://doi.org/10.1016/s0140-6736(11)61613-9
30 https://doi.org/10.1016/s1470-2045(13)70093-7
31 https://doi.org/10.1016/s1470-2045(14)70484-x
32 https://doi.org/10.1016/s1470-2045(16)30107-3
33 https://doi.org/10.1056/nejmoa1510665
34 https://doi.org/10.1158/1078-0432.ccr-11-0553
35 https://doi.org/10.1185/03007995.2014.977992
36 https://doi.org/10.1185/03007995.2016.1140028
37 https://doi.org/10.1200/jco.2004.06.132
38 https://doi.org/10.1200/jco.2008.21.4809
39 https://doi.org/10.1371/journal.pone.0184423
40 https://doi.org/10.2147/cer.s97885
41 https://doi.org/10.3111/13696998.2013.768530
42 schema:datePublished 2018-12
43 schema:datePublishedReg 2018-12-01
44 schema:description BACKGROUND: In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. METHODS: Progression-free survival (PFS) and overall survival (OS) in prior sunitinib-treated patients with mRCC were compared by conducting matching-adjusted indirect comparison (MAIC) analyses, including base-case and sensitivity analyses. Individual patient-level data from prior sunitinib-treated patients who received axitinib in AXIS were weighted to match published baseline characteristics of prior sunitinib-treated patients who received either cabozantinib or everolimus in METEOR. RESULTS: There was no statistically significant difference in PFS (aHR [adjusted hazard ratio] = 1.15 [CI: 0.82-1.63]) and OS (aHR = 1.00 [CI: 0.69-1.46]) between axitinib versus cabozantinib in the base-case analysis. In the sensitivity analysis, PFS (aHR = 1.39 [CI: 1.00-1.92]) and OS (aHR = 1.35 [CI: 0.95-1.92]) were shorter for axitinib compared with cabozantinib; however, the OS difference was not statistically significant. Axitinib was associated with significantly longer PFS compared with everolimus in the base-case (aHR = 0.53 [CI: 0.36-0.80]) and sensitivity analyses (aHR = 0.63 [CI: 0.45-0.88]), respectively. Results suggested an OS benefit for axitinib versus everolimus in base-case analyses (aHR = 0.63 [CI: 0.42-0.96]); however, the difference in OS in the sensitivity analysis was not statistically significant (aHR = 0.84 [CI: 0.59-1.18]). CONCLUSIONS: MAIC analyses suggest PFS and OS for axitinib and cabozantinib are dependent on the Memorial Sloan Kettering Cancer Center definition used; in the base-case analysis, there was no significant difference in PFS and OS between axitinib and cabozantinib. In the sensitivity analysis, PFS in favour of cabozantinib was significant; however, the trend for prolonged OS with cabozantinib was not significant. For axitinib and everolimus, MAIC analyses indicate patients treated with axitinib may have an improved PFS and OS benefit when compared to everolimus. Disparities between the base-case and sensitivity analyses in this study underscore the importance of adjusting for the differences in baseline characteristics and that naïve indirect comparisons are not appropriate.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree true
48 schema:isPartOf N3dc50adc946c4148a807aa1e14ed4a23
49 Nfb44f933342e4379ac844679e58da7c3
50 sg:journal.1024632
51 schema:name Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
52 schema:pagination 1271
53 schema:productId N0e79f47067b6402d92dfd76a4ff84a56
54 N59e1346de16448c69a8085e71e0f5f05
55 Nd4cf4cbaff244c26a0731ae78c50aae8
56 Nd51cf5f3e0494196ade05ffa529ef8d8
57 Nd7d229a3b79d498a92f939128898fa77
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110759467
59 https://doi.org/10.1186/s12885-018-5157-0
60 schema:sdDatePublished 2019-04-11T13:20
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N50f0c47b6e8f4df4b4f6386f827227de
63 schema:url https://link.springer.com/10.1186%2Fs12885-018-5157-0
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N01855a0b8dec430dbafbe4defc5f4980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Pyridines
69 rdf:type schema:DefinedTerm
70 N0293439949f046b3bec02298dac29b1b rdf:first sg:person.0756726716.47
71 rdf:rest N9a658b9bcb7146a083287319bfb992a4
72 N0e79f47067b6402d92dfd76a4ff84a56 schema:name readcube_id
73 schema:value 3ef2fb80629bf314a50551c6f0d3bd4837131769f19d8a673511f34415ded062
74 rdf:type schema:PropertyValue
75 N1d27006780c44477a4f54b635a6033bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Sunitinib
77 rdf:type schema:DefinedTerm
78 N34a193fdfecf4874a246ff7374668626 rdf:first sg:person.01255356274.07
79 rdf:rest rdf:nil
80 N384b6824adfa4659a86646f2536774da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Female
82 rdf:type schema:DefinedTerm
83 N3d2ad73210b44306b88b7060378d9c7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Axitinib
85 rdf:type schema:DefinedTerm
86 N3dc50adc946c4148a807aa1e14ed4a23 schema:issueNumber 1
87 rdf:type schema:PublicationIssue
88 N49ba93db5fbc4ce39ba7b797f4910dda schema:name University of Lyon, Centre Léon Bérard, Lyon, France
89 rdf:type schema:Organization
90 N4a3ada6418a443e38b1ecc6412a38175 schema:name Evidera, 7575 Trans-Canada Highway, Suite 404, H4R 1V6, Montreal, Quebec, Canada
91 rdf:type schema:Organization
92 N50f0c47b6e8f4df4b4f6386f827227de schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 N59e1346de16448c69a8085e71e0f5f05 schema:name pubmed_id
95 schema:value 30567533
96 rdf:type schema:PropertyValue
97 N680f30ed24c9440689cbb2088fba7643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Carcinoma, Renal Cell
99 rdf:type schema:DefinedTerm
100 N6b8675a6e589412fb5a25f3ccfdc4b40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 N6e1dab7abe3e4dbf9de786a47651a956 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Adult
105 rdf:type schema:DefinedTerm
106 N7e8d38bb1da54e0e825fb8ec6bd2f512 rdf:first sg:person.01132720503.65
107 rdf:rest Nfbe549a8394e4f80969b6136e1259312
108 N8740b4a7821542af9b6dad66cd2b2d5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Progression-Free Survival
110 rdf:type schema:DefinedTerm
111 N89ff103c60f940d7b2e24c19dcab254d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Disease-Free Survival
113 rdf:type schema:DefinedTerm
114 N9a658b9bcb7146a083287319bfb992a4 rdf:first sg:person.0600603143.74
115 rdf:rest N7e8d38bb1da54e0e825fb8ec6bd2f512
116 N9b3d1b4a71b94f3489aa2192a6b61a51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Everolimus
118 rdf:type schema:DefinedTerm
119 Na5be7009bcc14e19907dd1b80e23ab0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Aged
121 rdf:type schema:DefinedTerm
122 Naa318079822e41d4a7e01ffb30dfc165 rdf:first sg:person.01067707272.62
123 rdf:rest Nb86364dc68e1418eb67e211bfa868b7e
124 Nac04bdbc06ba4a608348b7191b881059 rdf:first sg:person.010375770560.48
125 rdf:rest N0293439949f046b3bec02298dac29b1b
126 Nb86364dc68e1418eb67e211bfa868b7e rdf:first sg:person.0723756046.31
127 rdf:rest Nac04bdbc06ba4a608348b7191b881059
128 Nb8a5c55fca8749b09db47c412d86db7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Anilides
130 rdf:type schema:DefinedTerm
131 Nc2801585b20841ea9956723627213a26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Proportional Hazards Models
133 rdf:type schema:DefinedTerm
134 Nd4cf4cbaff244c26a0731ae78c50aae8 schema:name nlm_unique_id
135 schema:value 100967800
136 rdf:type schema:PropertyValue
137 Nd51cf5f3e0494196ade05ffa529ef8d8 schema:name doi
138 schema:value 10.1186/s12885-018-5157-0
139 rdf:type schema:PropertyValue
140 Nd7d229a3b79d498a92f939128898fa77 schema:name dimensions_id
141 schema:value pub.1110759467
142 rdf:type schema:PropertyValue
143 Nec07896628dc49e9b8444d150a7c5aae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Male
145 rdf:type schema:DefinedTerm
146 Nf006f7859a264303a51665afd19c9cd0 rdf:first sg:person.0723163720.31
147 rdf:rest Naa318079822e41d4a7e01ffb30dfc165
148 Nfb44f933342e4379ac844679e58da7c3 schema:volumeNumber 18
149 rdf:type schema:PublicationVolume
150 Nfbe549a8394e4f80969b6136e1259312 rdf:first sg:person.01340453362.44
151 rdf:rest N34a193fdfecf4874a246ff7374668626
152 Nfe25197142d24e5b882cc2f5480cc830 schema:name Evidera, Budapest, Hungary
153 rdf:type schema:Organization
154 Nff494e8630c149e7b42c1cead3b1a854 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Middle Aged
156 rdf:type schema:DefinedTerm
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
161 schema:name Oncology and Carcinogenesis
162 rdf:type schema:DefinedTerm
163 sg:journal.1024632 schema:issn 1471-2407
164 schema:name BMC Cancer
165 rdf:type schema:Periodical
166 sg:person.010375770560.48 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
167 schema:familyName Bargo
168 schema:givenName Danielle
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010375770560.48
170 rdf:type schema:Person
171 sg:person.01067707272.62 schema:affiliation Nfe25197142d24e5b882cc2f5480cc830
172 schema:familyName Benedict
173 schema:givenName Agnes
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067707272.62
175 rdf:type schema:Person
176 sg:person.01132720503.65 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
177 schema:familyName Desai
178 schema:givenName Jigar
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132720503.65
180 rdf:type schema:Person
181 sg:person.01255356274.07 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
182 schema:familyName Larkin
183 schema:givenName James
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07
185 rdf:type schema:Person
186 sg:person.01340453362.44 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
187 schema:familyName Cappelleri
188 schema:givenName Joseph C.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340453362.44
190 rdf:type schema:Person
191 sg:person.0600603143.74 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
192 schema:familyName Ramaswamy
193 schema:givenName Krishnan
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600603143.74
195 rdf:type schema:Person
196 sg:person.0723163720.31 schema:affiliation N4a3ada6418a443e38b1ecc6412a38175
197 schema:familyName Proskorovsky
198 schema:givenName Irina
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723163720.31
200 rdf:type schema:Person
201 sg:person.0723756046.31 schema:affiliation N49ba93db5fbc4ce39ba7b797f4910dda
202 schema:familyName Negrier
203 schema:givenName Sylvie
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31
205 rdf:type schema:Person
206 sg:person.0756726716.47 schema:affiliation https://www.grid.ac/institutes/grid.420142.1
207 schema:familyName Sandin
208 schema:givenName Rickard
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756726716.47
210 rdf:type schema:Person
211 sg:pub.10.1007/s40263-013-0102-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048158014
212 https://doi.org/10.1007/s40263-013-0102-x
213 rdf:type schema:CreativeWork
214 sg:pub.10.1038/s41416-018-0164-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106858927
215 https://doi.org/10.1038/s41416-018-0164-0
216 rdf:type schema:CreativeWork
217 sg:pub.10.1186/1471-2288-12-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010370832
218 https://doi.org/10.1186/1471-2288-12-9
219 rdf:type schema:CreativeWork
220 sg:pub.10.1186/2162-3619-2-32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008593355
221 https://doi.org/10.1186/2162-3619-2-32
222 rdf:type schema:CreativeWork
223 sg:pub.10.2165/11592490-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024355436
224 https://doi.org/10.2165/11592490-000000000-00000
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1002/cncr.25219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017587632
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/j.clinthera.2015.09.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051027115
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1016/j.eururo.2007.03.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047653672
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1016/j.jval.2012.05.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017355577
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/s1470-2045(13)70093-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017252421
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1016/s1470-2045(14)70484-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043226190
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1158/1078-0432.ccr-11-0553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003173433
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1185/03007995.2014.977992 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025383996
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1185/03007995.2016.1140028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020375126
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2004.06.132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022235480
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2008.21.4809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003290766
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1371/journal.pone.0184423 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091532595
257 rdf:type schema:CreativeWork
258 https://doi.org/10.2147/cer.s97885 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037697585
259 rdf:type schema:CreativeWork
260 https://doi.org/10.3111/13696998.2013.768530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020783661
261 rdf:type schema:CreativeWork
262 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
263 schema:name Pfizer Inc, New York, NY, USA
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.420142.1 schema:alternateName Pfizer (Sweden)
266 schema:name Pfizer AB, Vetenskapsvägen 10, 191 90, Sollentuna, Sweden
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.5072.0 schema:alternateName Royal Marsden NHS Foundation Trust
269 schema:name Royal Marsden NHS Foundation Trust, London, UK
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...